Glycogen synthase kinase 3 beta (GSK3B) is a serine/threonine kinase involved in multiple signaling pathways, including Wnt, insulin, and growth factor signaling. It plays critical roles in cellular processes such as glycogen metabolism, cell proliferation, differentiation, and apoptosis. Dysregulation of GSK3B has been linked to neurodegenerative diseases (e.g., Alzheimer’s disease), cancer, diabetes, and mood disorders. Antibodies targeting GSK3B are essential tools for studying its expression, activity, and post-translational modifications in these contexts.
GSK3B exists in two isoforms (α and β) and is regulated by phosphorylation at specific residues. For example, phosphorylation at Ser9 inhibits its activity, while Tyr216 phosphorylation enhances it. Antibodies detecting total GSK3B or its phosphorylated forms (e.g., anti-pSer9-GSK3B or anti-pTyr216-GSK3B) are widely used to assess its functional state in experimental models. These antibodies are applied in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore GSK3B's role in disease mechanisms or drug responses.
Due to its involvement in tau phosphorylation (a hallmark of Alzheimer’s) and β-catenin degradation (linked to cancer), GSK3B antibodies are particularly valuable in neuroscience and oncology research. Validation of antibody specificity via knockout controls or peptide competition is crucial, as cross-reactivity with related kinases (e.g., GSK3A) may occur. Commercial GSK3B antibodies often specify reactivity across species (human, mouse, rat) and provide application-specific optimization data.